Ascendis Pharma (ASND) announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency, GHD, programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology, ESPE, and the European Society of Endocrinology, ESE, being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH in adults with chronic hypoparathyroidism; Week 52 growth and bone morphometry data from the pivotal ApproaCH Trial of TransCon CNP in children with achondroplasia; and efficacy and safety data from the Phase 3 foresiGHt Trial of TransCon hGH in adults with growth hormone deficiency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Strong Yorvipath Launch and Promising Pipeline Boost Buy Rating and Price Target
- Promising Outlook for Ascendis Pharma: Strong Yorvipath Sales and Positive Market Feedback Justify Buy Rating
- Ascendis Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
- Ascendis Pharma’s Earnings Call: Growth Amid Challenges
- Ascendis Pharma price target raised to $215 from $180 at Oppenheimer